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Owing to the prevalence of tumor-associated macrophages (TAMs)
in cancer and their unique influence upon disease progression and
malignancy, macrophage-targeted interventions have attracted no-
table attention in cancer immunotherapy. However, tractable targets
to reduce TAM activities remain very few and far between because
the signaling mechanisms underpinning protumor macrophage
phenotypes are largely unknown. Here, we have investigated
the role of the extracellular-regulated protein kinase 5 (ERK5) as a
determinant of macrophage polarity. We report that the growth
of carcinoma grafts was halted in myeloid ERK5-deficient mice.
Coincidentally, targeting ERK5 in macrophages induced a tran-
scriptional switch in favor of proinflammatory mediators. Further
molecular analyses demonstrated that activation of the signal
transducer and activator of transcription 3 (STAT3) via Tyr705
phosphorylation was impaired in erk5-deleted TAMs. Our study
thus suggests that blocking ERK5 constitutes a treatment strategy
to reprogram macrophages toward an antitumor state by inhibit-
ing STAT3-induced gene expression.
ERK5 | MAPK | STAT3 | macrophages | tumors
The inflammatory microenvironment is arguably one of themost influential components of most, if not all, tumors (1).
Central to cancer-related inflammation is a population of macro-
phages—namely, tumor-associated macrophages (TAMs)—which
primarily originate from blood monocytes that are continuously
recruited to the tumor site. In early tumors, TAMs display an in-
flammatory and tumoricidal “M1-like” phenotype. However, as
tumors progress, TAMs are functionally reprogrammed by tumor-
derived signals to exhibit a trophic, angiogenic, and immune-
inhibitory “M2-like” phenotype that contributes to further tumor
growth and malignancy (2). Accordingly, the detection of large
numbers of TAMs in cancer correlates with poor prognosis, but
also with a poor response of the tumor to anticancer agents (3).
Based on these observations, macrophage-targeted interventions
have been tested in preclinical models with encouraging results (4).
However, these strategies are limited because very few molecular
targets can be exploited therapeutically to discriminate between
different macrophage populations and specifically ablate the pres-
ence of TAMs in tumors. In particular, whereas a number of tran-
scription factors have been implicated in the rearrangement of the
transcriptional profile that sustains protumor TAM activities, the
signaling mechanisms that govern macrophage reprogramming to
aid disease progression are poorly understood.
Recently, the extracellular-regulated protein kinase 5 (ERK5)
has emerged as a critical component of prooncogenic signaling
(5). ERK5 belongs to the family of mitogen-activated protein
kinases (MAPKs) that play key roles in transducing extracellular
cues into a wide variety of cellular responses, including changes
in gene expression (6). The catalytic core of ERK5 situated in the
N-terminal half of the protein is most similar to that of the clas-
sical MAPKs ERK1/2. Despite this homology, ERK5 displays
several distinct structural and functional properties that set it apart
from ERK1/2 and the other members of the MAPK family. In
particular, its unique extended C terminus comprises two proline-
rich sequences, a bipartite nuclear localization sequence, and a
transcriptional activation domain (6). These features clearly in-
dicate unique mechanisms of downstream regulation of targets.
The importance of ERK5 in signal transduction was further sup-
ported by genetic evidence that the pathway exerts nonredundant
functions in vivo (7). Notably, consistent with its requirement for
the maintenance of vascular integrity during development, ERK5
was implicated in the neovascularization of melanoma and carci-
noma grafts by supporting endothelial cell survival (8, 9). More-
over, we have shown that suppressing inflammation by inducing
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erk5 deletion in neoplastic keratinocytes reduced tumor burden,
and this effect was potentiated by the concurrent administra-
tion of subtherapeutic doses of the chemotherapeutic agent doxo-
rubicin (10). This study is a demonstration that ERK5 in epithelial
cells can remodel the inflammatory microenvironment to sup-
port cancer development.
In parallel, other groups have shown that ERK5 can contribute
to immune cell fate. For example, ERK5 signaling mediates the
mitogenic response of macrophages to colony-stimulating factor 1
(CSF1) stimulation (11). Interestingly, CSF1-induced malignant
progression of murine mammary cancer was associated with en-
hanced infiltration of macrophages into primary mammary tumors
(12). Moreover, ERK5 has been implicated in the production of
proinflammatory mediators in endothelial cells and monocytes
(13). The differentiation of monocytes to functioning macro-
phages was found to be dependent on ERK5, but not ERK1/2,
signaling (14). The recent analysis of the LysMCre;erk5F/F mouse
model further showed that erk5-deleted bone marrow-derived
macrophages (BMDMs) displayed low-level expression of M2-
related genes, but increased expression of M1-related genes at
steady state, indicative of macrophage ERK5 favoring polarization
toward an M2 phenotype (15). Based on these findings, we in-
vestigated the possibility that ERK5 might also fuel cancer pro-
gression by enabling TAMs to acquire tumorigenic properties.
Results
Inactivation of ERK5 in the Myeloid Lineage Prevents Tumor Growth.
We used CD163 as a selective biomarker to detect macrophages
exhibiting a tumor-promoting and immunosuppressive pheno-
type (16) in formalin-fixed paraffin-embedded human tissue
blocks retrieved from the tissue bank of the Department of Pa-
thology (Azienda Socio Sanitaria Territoriale degli Spedali Civili
di Brescia, Brescia, Italy). These included transitional bladder
cancer (1 case), lung adenocarcinoma (2 cases), breast carci-
noma (4 cases), skin squamous cell carcinoma (SCC; 12 cases),
and normal skin (4 cases). We found a significant association
between CD163 (blue) and ERK5 (brown) expression in human
cancer (Fig. 1 A–F and H). Quantification of the immunos-
taining confirmed an increased number of CD163+ macrophages
exhibiting nuclear ERK5 in SCC compared with normal skin
tissue (Fig. 1 G–I). To investigate the functional relevance of
macrophage ERK5 in tumor development, we developed a
murine model in which the erk5 gene could be selectively ablated
in the myeloid lineage. This was achieved by crossing mice har-
boring LoxP sites in the erk5 allele [referred to as the flox (F)
allele; ref. 17] with animals carrying a Cre transgene inserted into
the ATG start site of the M lysozyme (LysM) gene (18) to
generate LysMCre+/−;erk5F/F animals. The recent analysis of the
LysMCre+/−;erk5F/F mouse model showed that macrophage ERK5
deficiency tipped the balance in favor of an M1 phenotype at
steady state (15). In contrast, no notable difference was reported
in total blood cell counts between LysMCre+/−;erk5F/F mice and
nontransgenic littermate controls. Moreover, the two geno-
types displayed similar numbers of monocytes (CD115+/Gr1+)
in bone marrow and a similar level of peritoneal fluid F4/80+
macrophages (15). Immunoblot analysis confirmed the loss of
ERK5 expression in LysMCre+/−;erk5F/F BMDMs at day 7 in
culture (Fig. 2A).
Melanoma 4434 cells isolated from a transgenic mouse line
carrying the BrafV600E mutation (a gift from Professor Richard
Marais, Cancer Research UK Manchester Institute, Manchester;
ref. 19) or LL/2 cells derived from a murine Lewis lung carcinoma
(20) were injected s.c. in the flanks of syngeneic erk5F/F or
LysMCre+/−;erk5F/F C57BL/6 animals. We observed that tumor
growth was markedly impeded in the absence of macrophage
ERK5, as demonstrated by a significant reduction in tumor vol-
ume in LysMCre+/−;erk5F/F mice compared with control erk5F/F an-
imals (Fig. 2 B and C). Postmortem studies confirmed that
macrophage ERK5 deficiency caused a significant decrease in
tumor weight (Fig. 2 B and C). To further characterize the tumor
growth defect associated with myeloid erk5 deletion, excised
carcinoma grafts were processed by immunofluorescence stain-
ing (Fig. 2D). Antibodies to the endothelial cell-specific marker
CD34 and to Iba1, a commonly used cell surface marker to label
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Fig. 1. ERK5 is highly expressed in human TAMs. (A–
H) Biopsies obtained from human carcinomas and
from normal skin were coimmunostained for ERK5
(brown) and the macrophage marker CD163 (blue).
Sections were counterstained with hematoxylin. Ar-
rows point to CD163+ macrophages exhibiting strong
expression of ERK5 in the nucleus. Compared with
cutaneous SCC, only a minor fraction of CD163+ mac-
rophages in normal skin express nuclear ERK5 (G–I);
strong cytoplasmic ERK5 is observed in dermal mast
cells. [Original magnification: 200× (G; Scale bar, 100 μm),
400× (A–C and H; scale bar, 50 μm; D–F are digital
magnification from the corresponding micropho-
tograph above), and 600× (G and H, Insets).] (I) For
quantitative analysis, double positive (ERK5+ and
CD163+) cells were counted in 4 normal skin (G) and 5
SCC cases (H) within a total area of 1 mm2, corre-
sponding to 5 high-power fields (HPF). The mean per
HPF ± SD was calculated. *P = 0.002 compares the
percentage of CD163+ cells expressing ERK5 in SCC and
in normal skin.
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total TAMs (21, 22), were utilized to visualize angiogenesis and
tumor macrophage infiltration. The results showed that tumor
vasculature and TAM density were both reduced by ∼50% in tu-
mors derived from LysMCre+/−;erk5F/Fmice compared with controls
(Fig. 2D). Collectively, these observations strongly suggested a link
between ERK5 and macrophages to support tumor growth.
Protumor Macrophage Polarization Is Dependent on ERK5. Next, the
impact of myeloid ERK5 deficiency on the accumulation of
immune cells in tumors was analyzed by using isolated cells from
tumor grafts that were gated for live cell analysis (Fig. S1A). Gr1
and F4/80 were used as markers for identification of granulocytes
(Gr1+/F4/80−), monocytes (Gr1+/F4/80+), and macrophages
(Gr1−/F4/80+) (23, 24). Consistent with Iba1 staining (Fig. 2D),
carcinoma and melanoma grafts extracted from LysMCre+/−;erk5F/F
mice exhibited a significantly lower number of macrophages com-
pared with tumors from control animals (Fig. 3 A and B and Fig.
S1D). In contrast, no marked difference was detected in the
number of granulocytes and monocytes between the two gen-
otypes (Fig. 3B and Fig. S1D). Further analysis of the sorted
F4/80+ macrophage population demonstrated that the absence
of ERK5 did not affect the proportion of CD11b+ TAMs in car-
cinoma (Fig. 3 C and D). We subsequently utilized CD206 to
distinguish tumor-supportive M2-like macrophages (25). The data
showed that 40% of Gr1−/F4/80+ macrophages in carcinoma de-
rived from erk5F/Fmice were positive for CD206 staining (Fig. 3C),
while only 13% were identified as TAMs on the M2 spectrum in
tumor grafts from LysMCre+/−;erk5F/F mice (Fig. 3D). Tumor-
promoting macrophages contribute to cancer development and
progression by producing growth factors and immunosuppressive
mediators which stimulate tumor cell proliferation and angio-
genesis, while dampening the immune response to the tumor (2,
3). Therefore, to determine whether the polarization defect
caused by ERK5 deficiency correlated with changes in transcrip-
tion, we measured the mRNA expression level of various M2
markers in F4/80+ cells purified by magnetic-assisted cell sorting.
We found that macrophages isolated from carcinoma grafts de-
rived from LysMCre+/−;erk5F/F mice exhibited a notable down-
regulation of arginase-1 (Arg-1), Fos-related antigen 1 (Fra1),
transforming growth factor β (Tgfβ), Il-10, and vascular endothe-
lial growth factor-a (Vegf-a) mRNAs (Fig. 3E). Interestingly,
this correlated with a significant up-regulation of certain M1
markers—e.g., inducible nitric oxide synthase (iNos), monocyte
chemoattractant protein-1 (Mcp-1), and Il-12β (Fig. 3E)—in-
dicating that ERK5 not only controlled TAM density, but also
maintained the M2 subtype of TAMs in tumors.
To provide direct evidence of the protumoral role of macro-
phage ERK5, we switched to an in vitro system that allowed
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Fig. 2. ERK5 expression in myeloid cells supports
tumor growth in vivo. (A) Immunoblot analysis
comparing the level of ERK5 expressed in macro-
phages obtained from the bone marrow of erk5F/F
and LysMCre+/−;erk5F/F animals. Total ERK1/2 expres-
sion was used as a loading control. (B and C) The
4434 melanoma (B) or LL/2 carcinoma (C) cells were
s.c. implanted into the back of erk5F/F mice that did
or did not carry the LysMCre transgene. The growth
of tumor grafts was monitored over time after initial
cell injection. The data correspond to the mean of
tumor volume ± SD (n = 5 mice in each group).
Representative pictures of tumor grafts and the
mean of tumor weight ± SD excised from erk5F/F and
LysMCre+/−;erk5F/F mice killed at the end of the ex-
periment are shown. (D) Sections of carcinoma grafts
were analyzed by immunofluorescence using specific
antibodies to CD34 (Left) and the pan macrophage
marker Iba1 (Right). The immune complexes were
detected with a secondary antibody conjugated to
Cy3 (red). DNA was stained with DAPI (blue). (Scale
bars, 50 μm.) The immunofluorescent signal corre-
sponding to CD34 or Iba1 was quantitated with
ImageJ. The data correspond to the mean ± SD (n =
3 tumors). *P < 0.05 (compares tumor grafts from
erk5F/F and LysMCre+/−;erk5F/F mice).
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characterization of cell-autonomous effects. Bone marrow cells
were isolated from femurs of CMV-CreER;erk5F/Fmice. Ablation of
ERK5 was induced by incubating the cells with 4-hydroxytamoxifen
(4-HT) (Fig. S2A). This did not prevent the maturation of bone
marrow cells in vitro (Fig. S2B). We used IL-6 and leukemia in-
hibitory factor (LIF), or tumor cell-conditioned medium, to po-
larize F4/80+/CD115+ macrophages toward a trophic, angiogenic,
and immune-inhibitory M2d-like or TAM phenotype, respectively
(26, 27). Inflammatory and tumoricidal M1 macrophages were
obtained by activation with IFN-γ in combination with lipopoly-
saccharide (LPS) (23). Nonpolarized macrophages growing in
complete medium were used as controls. The phenotypes
were confirmed by flow-cytometry staining of surface (F4/80 and
CD86) and intracellular (CD206) markers (Fig. S3). Interestingly,
the intensity of F4/80 staining was slightly higher in activated
erk5Δ/Δ compared with erk5F/F macrophages. This was consistent
with our previous observation suggesting that the loss of erk5
notably advanced macrophage differentiation in vitro (Fig.
S2B). Additionally, ERK5 deficiency caused a reduction in the
number of CD206+ macrophages (Fig. S3), confirming a role of
ERK5 in protumor macrophage activation.
To distinguish specific features of macrophages activated by IL-
6 and LIF, and of TAMs generated upon exposure to melanoma-
conditioned medium, we analyzed the level of expression of
M2 markers by quantitative real-time PCR. We confirmed that IL-
6 and LIF-induced macrophages exhibited M2d-like characteris-
tics, as demonstrated by elevated expression of CC chemokine
ligand 5 (Ccl5), chemokine (C-X-C motif) ligand 10 (Cxcl10),
matrix metalloproteinase 9 (Mmp9), and indoleamine 2,3-dioxy-
genase (Ido-1) mRNAs compared with M2a macrophages induced
by IL-4 (Fig. 4A and Fig. S4). No significant induction of Cxcl16 in
M2d polarized macrophages was observed (Fig. S4). Typical of
M2 polarization, M2d macrophages and TAMs expressed high
levels of Fizz-1and Ym-2 (Fig. S4). Compared with M2d macro-
phages, TAMs expressed more immunosuppressive (e.g., Tgfβ, Il-
10, and Arg-1) and trophic (e.g., Vegf-a and Mmp9) factors (Fig.
4A and Fig. S4), but similar amounts of Ido-1 (Fig. S4). Likewise,
TAMs generated upon exposure to carcinoma-conditioned
medium exhibited high levels of Arg-1, Tgfβ, Il-10, and Vegf-a
(Fig. S5A). Accordingly, melanoma-induced TAMs produced
more TGFβ, IL-10, and VEGF than M2d macrophages (Fig. 4B).
Consistent with our in vivo data (Fig. 3E), erk5Δ/Δ M2d and erk5Δ/Δ
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Fig. 3. ERK5 suppression specifically reduces the
relative fraction of M2 tumor-supportive macro-
phages in vivo. (A) Representative flow-cytometry
analysis and quantification of live (DAPI−) myeloid
cell populations in carcinomas 24 d after s.c. in-
oculation of LL/2 cells in erk5F/F and LysMCre+/−;erk5F/F
mice. (B) Graphical analysis of A showing a reduced
TAM fraction in carcinoma grafts excised from
LysMCre+/−;erk5F/F mice. The data correspond to the
mean ± SD (n = 3 tumors). (C and D) Flow-cytometry
analysis of tumor-derived macrophages from erk5F/F
(C) and LysMCre+/−;erk5F/F (D) mice after sorting
with magnetic microbeads ultrapure conjugated to
antibodies against F4/80. The expression of CD11b
and CD206 (continuous line) in sorted Gr1−/F4/80+
cells from B and C was defined by increased staining
over the isotype control (dotted line). (E) Quantita-
tive PCR (qPCR) analysis of multiple M1 and
M2 markers in Gr1−/F4/80+ sorted macrophages from
tumor grafts. The data correspond to the mean ± SD
(n = 3 tumors). *P < 0.05 (compares tumor grafts
from erk5F/F and LysMCre+/−;erk5F/F mice).
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TAMs failed to fully up-regulate these hallmark markers of pro-
tumor macrophage activities (Fig. 4A and Figs. S4 and S5A).
Notably, the secretion of TGFβ, IL-10, and VEGF by polarized
macrophages was significantly impaired in the absence of ERK5
(Fig. 4B). In contrast, erk5Δ/Δ TAMs exhibited increased expres-
sion of proinflammatory M1 factors (iNos,Mcp1, and Il-12β) (Fig.
4C and Fig. S5B). These data supported the idea that ERK5 acted
as a switch to turn on protumor macrophage properties, while
shutting down antitumor immunity.
Activated macrophage supernatants were subsequently col-
lected and added onto melanoma or carcinoma cells plated at
very low density (Fig. S2C). As expected, supernatants from
M2d-like macrophages or TAMs stimulated the proliferation of
cancer cells (Fig. 5A and Fig. S5C). This was significantly im-
paired in response to supernatants from similarly polarized
erk5Δ/Δ macrophages (Fig. 5A and Fig. S5C). Moreover, erk5Δ/Δ
macrophages exposed to IL-6 and LIF, or to melanoma cell-
conditioned medium, exhibited a reduced ability to protect
4434 cells against vemurafenib (PLX4032) treatment compared
with erk5F/F macrophages activated under the same conditions
(Fig. 5 B and C). Likewise, pharmacological inhibition of
ERK5 using the novel JWG-045 compound (28) impaired the
ability of human TAMs to support melanoma cell proliferation
and to protect melanoma cells against PLX4032 toxicity (Fig.
S6), thereby demonstrating the therapeutic implication of our
findings. In contrast, supernatants from nonpolarized or M1
macrophages displayed no trophic activity toward murine or
human tumor cells (Fig. 5A and Figs. S5C and S6A) and pro-
vided no protection to murine 4434 melanoma cells against
PLX4032 (Fig. 5 B and C). We observed a slight protective effect
of nonpolarized macrophage supernatant in human A375 cells
incubated with PLX4032, but this was independent of ERK5
(Fig. S6 B and C). Collectively, these data demonstrated the
requirement of ERK5 for macrophages to acquire tumor-
promoting activities in response to tumor-derived signals.
STAT3 Activation Is Impaired in ERK5-Deficient Macrophages. Central
to macrophage activation and immune receptor signaling path-
ways are the transcription factors of the signal transducer and
activator of transcription (STAT) family. In particular, STAT3 is
activated upon phosphorylation at Tyr705 by protein kinases of
the JAK family, enabling nuclear translocation and induction of
genes associated with protumor macrophage phenotypes, while
suppressing proinflammatory markers (29, 30). Consistently,
STAT3 was tyrosine-phosphorylated and accumulated in the
nuclei of macrophages stimulated with IL-6 and LIF (Fig. 6 A
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Fig. 4. ERK5 deficiency in macrophages impairs the
production of protumoral factors. erk5F/F and erk5Δ/Δ
macrophages were polarized with IL-6 + LIF (M2d),
IL-4 (M2a), or 4434 cell-conditioned medium (TAMs).
Nonpolarized (NP) macrophages were used as con-
trols. (A and C) The expression of M2 (A) and M1
(C) markers was analyzed by qPCR. The data corre-
spond to the mean ± SD of three (A) or two (C) in-
dependent experiments performed in triplicate.
(B) The secretion of TGFβ, IL-10, and VEGF by NP and
M2d macrophages or by TAMs was measured by
ELISA. The data represent the mean ± SD of three
independent experiments. *P < 0.05 (compares
polarized erk5F/F vs. erk5Δ/Δ macrophages).
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and B). Remarkably, this was prevented in the absence of ERK5
(Fig. 6 A and B and Fig. S7 A and B). In contrast, erk5F/F and
erk5Δ/Δ macrophages displayed similar levels of STAT3 phos-
phorylation at Ser727 and ERK1/2 phosphorylation at the Thr-
Glu-Tyr (TEY) motif, suggesting that the loss of ERK5 expres-
sion did not cause a general defect in IL-6 signaling (Fig. 6A).
We confirmed by flow cytometry that erk5F/F and erk5Δ/Δ mac-
rophages exhibited a comparable level of expression of the
common gp130 subunit, a transmembrane protein that interacts
with the IL-6 receptor for signal transduction (Fig. S7C). As
expected, we found no evidence that IL-4 activated STAT3 in
macrophages (Fig. 6A). Nonetheless, like IL-6 and LIF, IL-4 in-
duced STAT3 phosphorylation at Ser727 and phosphorylation of
ERK1/2 independently of ERK5 (Fig. 6A).
Increased STAT3 phosphorylation in macrophages exposed to
LL/2-conditioned medium was also impaired by genetic in-
activation of the erk5 allele (Fig. 6C) or pharmacological in-
hibition of ERK5 activity (Fig. S8A). Additionally, ERK5
deficiency prevented JAK2 phosphorylation at Tyr1007/1008 (Fig.
6C). Therefore, we tested the possibility that ERK5 controlled
STAT3 phosphorylation by blocking the expression of negative
regulators of the JAK/STAT pathway. These include suppressors
of cytokine signaling (SOCS), a family of cytokine-inducible pro-
teins which have been implicated in shaping M1/M2 macro-
phage polarization via negative-feedback loops (31). For example,
SOCS3 suppressed IL6R-mediated STAT3 activation (31).
Moreover, reduced expression of SOCS3 in macrophages corre-
lated with the induction of M2-type phenotypes (32, 33). Here, we
observed a slight increase in SOSC3 protein expression in mac-
rophages stimulated with IL-6 and LIF (Fig. S8B). This was clearly
enhanced upon pharmacological inhibition of ERK5 (Fig. S8B).
Consistently, LL/2-stimulated erk5Δ/Δ macrophages exhibited an
elevated level of Socs3 transcript (Fig. S8C). In parallel, we ex-
amined the expression of the Krüppel-like factor 4 (KLF4), a
known downstream target of ERK5 (34) which cooperates with
STAT6 to up-regulate M2 genes, in particular Arg-1 and Fizz-1,
while inhibiting M1 genes such as iNos, in response to IL-4 stim-
ulation (35). We found no evidence that klf4 was involved in
mediating the response of macrophages to tumor-derived signals
(Fig. S8C).
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Fig. 5. ERK5 is required for macrophage-induced
tumor cell proliferation and drug resistance. (A and
B) Colony formation assay of murine 4434 melanoma
cells incubated for 7 d with supernatants (SN) from
nonpolarized (NP) macrophages or from macro-
phages activated with IFNγ + LPS (M1), IL-6 + LIF
(M2d), or 4434 cell-conditioned medium (TAMs). The
4434 cells growing in low-serum medium were used
as controls. Where indicated, PLX4032 (PLX; 1 μM)
was added to the medium for the duration of the
assay. (C) The 4434 cell cytotoxicity was determined
by using CellTox green and analyzed with Gen5. The
data correspond to the mean ± SD of two in-
dependent experiments performed in triplicate. *P <
0.05 (compares tumor cell proliferation induced by
SN from polarized erk5F/F vs. erk5Δ/Δ macrophages).
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The role of ERK5 in controlling STAT3-mediated transcrip-
tion was further demonstrated by luciferase reporter assay in
HeLa cells exhibiting inducible expression of full-length (FL)
ERK5 (Fig. S8D). The catalytic activity of ERK5 was required to
mediate this effect, given that enhanced transcription by STAT3
in EGF-stimulated cells was blocked by pretreatment with
XMD8-92 at a concentration reported to inhibit ERK5 with
limited off target effect on BRD4 (Fig. S8D and ref. 28). In-
terestingly, ectopic expression of a C-terminal truncated mutant
of ERK5 (ERK5-ΔC) failed to enhance STAT3 activity to the
same level as observed with ERK5-FL (Fig. S8D), indicative of
the involvement of the C-terminal region of ERK5 in mediating
STAT3-increased transcription.
ERK5-Dependent Regulation of STAT3 Underpins Protumor Macrophage
Activation. Our previous findings convincingly demonstrated a
genetic link between ERK5 and STAT3 signaling in macrophages.
To test whether ERK5 activation promoted M2 subtype polari-
zation via STAT3, we generated macrophages carrying a trans-
gene encoding a constitutive active (ca) mutant MEK5 fused with
green fluorescent protein (GFP) (36). Importantly, a PGK-Neo-
STOP cassette flanked with LoxP sites was placed in front of the
caMEK5-GFP CDNA to enable caMEK5 expression in a tem-
porally controlled manner. Induced caMEK5 expression in CMV-
CreER;caMEK5F/F macrophages incubated with 4-HT caused
ERK5 hyperphosphorylation and increased STAT3 phosphoryla-
tion at Tyr705 (Fig. 6D). This primed macrophage polarization
toward the M2 subtype, as evidenced by elevated secretion of
M2 markers following exposure to LL/2-conditioned medium (Fig.
6D). This effect was abolished following pharmacological in-
hibition of MEK5 by BIX02189 (Fig. 6D). A similar observation
was made in ERK5-deficient macrophages coinfected with ade-
noviruses encoding Flag-tagged wild-type (WT) ERK5 and HA-
tagged caMEK5 (Fig. S9). In contrast, HA-caMEK5 failed to
phosphorylate STAT3 and to increase the level of M2 transcripts
in macrophages expressing a dominant negative mutant form of
ERK5 (F-ERK5-AEF) (Fig. S9 B and C).
To confirm the importance of STAT3 to activate M2d macro-
phage and TAM polarization, we tested the requirement of STAT3
in controlling M2 marker expression. STAT3 activity was inhibited
by preincubating the cells with S3I-201 (Fig. S10A). We found that
S3I-201 significantly impaired increased expression of Arg-1, Tgfβ,
and Il-10 transcripts in response to IL-6 and LIF stimulation, or
following exposure of macrophages to LL/2-conditioned medium
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Fig. 6. STAT3 phosphorylation at Tyr705 in macro-
phages is dependent on ERK5 signaling. (A–C) After
starvation in 1% FBS medium overnight, erk5F/F and
erk5Δ/Δ macrophages were stimulated with IL-6 and
LIF, or IL-4, or exposed to LL/2-conditioned medium
(LL/2) for 30 min, as indicated. Nonstimulated (NS)
macrophages were used as controls. (A and C) Protein
lysates were analyzed by immunoblot with indicated
antibodies. Similar results were obtained in two in-
dependent experiments. (B) Immunofluorescence was
performed with a specific antibody to pSTAT3(Y705).
The immune complexes were detected with a secondary
antibody conjugated to Cy3 (red). DNA was stained with
DAPI (blue). (Scale bars, 10 μm.) (D) CMV-CreER;caMEK5F/F
macrophages were mock-treated (−) or incubated with
4-HT (0.1 μM; +) at day 5 in culture for 48 h. Protein ly-
sates were analyzed by immunoblot with antibodies
against GFP, ERK5, pSTAT3(Y705), STAT3, and tubulin.
Similar results were obtained in two independent ex-
periments. Alternatively, the cells were incubated with
BIX02189 (1 μM; BIX), as indicated, for 2 h before being
exposed to LL/2-conditionedmedium (LL/2). Nonpolarized
(NP) macrophages were used as controls. After 36 h,
macrophages were rinsed with PBS and cultured in
DMEM supplemented with 5% FBS for a further 24 h.
The amount of TGFβ, IL-10, and VEGF secreted in super-
natants was quantified by ELISA. The data represent
the mean ± SD of two independent experiments. *P <
0.01 (compares differences between treatments).
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(Fig. 7A). We also analyzed STAT3 activation in tumor-
infiltrated macrophages. We used Iba1 to detect TAMs in sec-
tions of murine carcinoma grafts. The data showed that the per-
centage of TAMs (red) exhibiting phospho-Tyr705 STAT3 (green)
significantly decreased in tumors excised from LysMCre+/−;erk5F/F
animals (Fig. 7B and Fig. S10B). To evaluate whether this finding
was clinically relevant, we analyzed biopsies of human SCC (Fig.
1H). Consistent with the idea that STAT3 activation is dependent
on ERK5, we found a high proportion of CD163+ macrophages
coexpressing ERK5 and phospho-Tyr705 STAT3 in human skin
tumors (Fig. 7C).
Discussion
This investigation into the signaling mechanisms by which mye-
loid cells contribute to tumorigenesis has led us to uncover a role
for ERK5 signaling in regulating the functionality of protumor
macrophages in cancer. This is substantiated by our demonstration
that macrophages rely on ERK5 to produce trophic and immu-
nosuppressive factors. Moreover, ERK5 activation caused by ec-
topic expression of caMEK5 in macrophages enhanced the
secretion of M2 markers after stimulation with IL-6 and LIF or
exposure to LL/2-conditioned medium. ERK5-mediated Arg-1
and Vegf-a expression may support tumor growth by providing the
substrates for cancer cells and by inducing neovascularization.
Accordingly, decreased tumor growth observed in LysMCre;erk5F/F
mice as a consequence of impaired protumor macrophage acti-
vation correlated with the lessened ability of Δerk5 macrophages
to support tumor cell proliferation and tumor angiogenesis. Ad-
ditionally, an ERK5-dependent increase in Tgfβ and Il-10 ex-
pression may be critical to establish an immune-suppressive
microenvironment that dampens effective antitumor T cell re-
sponses. For this reason, interesting future directions may include
investigating the effect of selective blockade of ERK5 in myeloid
lineage cells on tumor infiltration of T cells exhibiting cytotoxic
activities. Further analyses of the antitumor immune response in
combinatory studies looking at the synergetic effect of targeted
inhibition of ERK5 in macrophages with new immune checkpoint
inhibitors, such as anti-PDL1 and -CTL4 antibody therapies,
would have obvious therapeutic implications (37). In addition to
contributing to tumorigenesis, TAMs play a critical role in tumor-
drug resistance and disease relapse after therapy (3, 4). In this
study, we have found that TAMs lacking ERK5 exhibited a re-
duced ability to protect melanoma cells against vemurafenib.
Consequently, it may also be possible to enhance the responsive-
ness of tumors to first-line therapy by inhibiting ERK5 in mac-
rophages. In light of our findings, we believe that these additional
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Fig. 7. STAT3 is phosphorylated at Tyr705 in TAMs. (A)
erk5F/F macrophages were preincubated with S3I-201
(50 μM; Selleck) for 2 h before being stimulated with
IL-6 and LIF or with LL/2-conditioned medium (LL/2) for
1 h. Nonstimulated (NS) macrophages were used as
controls. Expression of M2 markers was analyzed by
qPCR. The data correspond to the mean ± SD of three
independent experiments performed in triplicate. *P <
0.05 [compares cells mock-treated (vehicle) vs. treated
with S3I-201]. (B) Carcinoma grafts excised from erk5F/F
and LysMCre+/−;erk5F/F mice were processed by immuno-
fluorescence with specific antibodies to pSTAT3(Y705) or
to the pan macrophage marker Iba1. The immune
complexes were detected with Fluorescein Avidin D
(green) or Texas Red Avidin D (red). DNA was stained
with DAPI (blue). (Scale bars, 10 μm.) B, I–VI are digital
magnifications from the corresponding microphoto-
graph. (Scale bars, 15 μm.) Arrows indicate pSTAT3(Y705)
positive macrophages. (C) Serial sections obtained
from biopsies of human SCC (four cases) were
immunostained for ERK5 (brown;Upper) or pSTAT3(Y705)
(brown; Lower), coupled with the macrophage marker
CD163 (blue). Two HPFs are shown, and the arrows/
arrowheads identify two ERK5+pSTAT3+CD163+
triple-positive cells. (Original magnification: 400×;
scale bars, 50 μm.) The frequency of double-positive
macrophages for ERK5 (circle) or pSTAT3 (square) in
three distinct corresponding tumor areas (indicated by
black, black/white, and white) is reported in the graph.
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studies will establish ERK5 as an important drug target in com-
bination with immune-based therapies and conventional che-
motherapy and radiotherapy to achieve long-term control of
malignancy and durable remission for cancer patients.
Our discovery that ERK5 signaling was required for STAT3
phosphorylation at Tyr705 further underscored its crucial role in
tumor macrophage activation. Indeed, stat3 gene deletion in bone
marrow cells caused antitumor immune response and significant
growth inhibition of melanoma grafts (38). Moreover, STAT3 ac-
tivation in the immune microenvironment was previously associ-
ated with TAMs on the M2 spectrum (29, 39). Accordingly, we
found that STAT3 inhibition suppressed increased expression of
M2 markers in macrophages stimulated with IL-6 and LIF or with
LL/2-conditioned medium. We predict that, in addition to re-
quiring ERK5 catalytic activity, the transactivation domain located
in the C-terminal region of ERK5 may be important for the ac-
quisition of M2-like markers downstream of STAT3 (40). More-
over, we observed that JAK2 activation by phosphorylation was
impaired in Δerk5 macrophages. Conversely, SOCS3 expression
was increased after genetic inactivation of erk5 or inhibition of
ERK5 activity. Interestingly, up-regulation of SOCS3 has been
associated with increased expression of the M1 marker, iNos (32).
A key role of SOCS3 in M1 polarization was further supported by
evidence that reduced expression of SOCS3 in macrophages cor-
related with the induction of M2-type phenotypes (33). Therefore,
ERK5-mediated suppression of SOCS3 expression is in line with
the priming of TAMs to elicit protumorigenic activities via JAK/
STAT3 signaling. This hypothesis is consistent with the genetic
demonstration that hyperactivation of STAT3 in macrophages
caused by SOCS3 deficiency produced less inflammation (41).
However, in contrast to expectation, this study showed that mye-
loid suppression of SOCS3 prevented cancer metastasis through
promoting antitumor immunity (41). This finding highlights the
great difficulty in predicting the impact of immune receptor sig-
naling in tumor biology. Hence, further experiments will be
required to rigorously establish the importance of SOCS3 in
ERK5-induced macrophage activation associated with malignancy.
Overall, our in vitro approach has modeled the effect of
STAT3-activating cytokines (i.e., IL-6 and LIF) produced by
tumor cells on macrophages. However, many regulated genes
induced by STAT3 activate the same cytokine–STAT3 pathway
in autocrine and paracrine feed-forward loops going between
tumor cells and tumor-interacting immune cells (30, 38). For
example, tumor epithelial expression of STAT3 elicits an anti-
tumor immune response involved in mammary tumor growth and
breast cancer metastasis (42). We have previously demonstrated
that ERK5 was required in neoplastic epithelial cells to propa-
gate tumor-associated inflammation through the production of
two major neutrophil chemoattractants, namely, CXCL1 and
CXCL2, and increased expression of component of the IL-1/
COX-2 pathway (10). Furthermore, our current analysis of hu-
man cancer biopsies showed a number of tumor cells exhibiting
high ERK5 expression and strong phosphorylation of STAT3 at
Tyr705. These findings directly impact the question of whether
the cross-talk between ERK5 and STAT3-mediated signal
transduction also forms a critical axis in cancer cells to control
and shape the local tumor microenvironment. Therefore, the
role of ERK5-dependent epithelial STAT3 activation as a
mechanism to reduce tumor immunogenicity and evade immune
surveillance will deserve further exploration.
Materials and Methods
Tumor Grafts and Isolation of Single Cells from Mouse Tumors. Mice were
inoculated in the flanks with 5 × 105 LL/2 carcinoma cells or 5 × 106
4434 melanoma cells. All animal procedures were performed under license
in accordance with the UK Home Office Animals (Scientific Procedures) Act
(1986) and approved by the Animal Welfare and Ethical Review Body of the
University of Manchester, Manchester, United Kingdom. Tumor size was
determined by caliper measurements of tumor length, width, and depth,
and volume was calculated as follows: volume = 0.5236 × length × width ×
depth (millimeters). To characterize tumor-infiltrating immune cells, mice
were euthanized 24 d after tumor cell injection. Tumors (0.5 g) were iso-
lated, minced in a Petri dish on ice, and enzymatically dissociated in HBSS, as
described (43). The duration of enzymatic treatment was optimized for
greatest yield of live F4/80+ cells per tumor type. After neutralization with
1% BSA containing HBSS, cell suspensions were filtered through a 70-μm cell
strainer. Red blood cells were solubilized with red cell lysis buffer (Pharm
Lyse; BD Biosciences), and the resulting suspension was filtered through a
cell strainer to produce a single-cell suspension. Cells were washed once with
PBS before use in flow-cytometry analysis or magnetic bead purification.
Magnetic Bead Purification of TAMs. Single-cell preparations from tumors
were incubatedwith FcR-blocking reagent (mouse seroblock FcR; Bio-Rad) for
15 min and then with 20 μL of magnetic microbeads ultrapure conjugated to
an antibody against F4/80 (catalog no. 130-110-443; Miltenyi Biotec MACS
Microbeads) per 107 cells for 30 min at 4 °C. After washing, cells bound to
magnetic beads were purified according to the manufacturer’s instructions.
Flow Cytometry. Mononuclear single-cell suspensions were analyzed by
fluorescence-activated cell sorting (FACS). In brief, cells were pelleted,
washed twice, and resuspended in MACS solution (PBS containing 10% FBS
and 1 mM EDTA). Cell viability was assessed by Trypan blue exclusion or DAPI
(catalog no. D1306; Molecular Probes) to discriminate dead from live cells. For
surface staining, cells were incubated with an anti-mouse FcR antibody
(mouse seroblock FcR; Bio-Rad) for 20 min at 4 °C, before being stained with
the following antibodies conjugated to phycoerythrin (PE): CD115-PE (cat-
alog no. MCA1898PET; Bio-Rad), CD86-PE (catalog no. A16385; Molecular
Probes), CD130-PE (catalog no. 12-1302-80; eBioscience), CD11b-PE (catalog
no. 12-0112-81; eBioscience), Gr1-PE (anti-mouse Ly-6G and Ly-6C; catalog
no. 553128; BD-Pharmingen), and F4/80-Alexa Fluor 488 (catalog no.
MF48020; Life Technologies). For intracellular staining, cells were blocked
with the anti-mouse FcR antibody in permeabilization buffer (eBioscience)
for 45 min at 4 °C, before incubation with anti–CD206-PE (catalog no.
MCA2235PET; Bio-Rad). Flow-cytometry analysis was carried out with a BD
FACScan instrument and analyzed by using the FlowJo software.
Colony Formation and Cell Cytotoxicity Assays. Tumor cells were plated in 12-
well plates (colony formation assay) or in clear-bottom, black, 96-well plates
(cell cytotoxicity assay) and allowed to adhere overnight in DMEM complete
medium. The next day, the medium was replaced with control medium con-
taining 2% or 5% FBS or with medium derived from nonpolarized, M1 or M2d
polarized macrophages, or from TAMs (1/2 diluted). Where indicated,
vemurafenib (PLX4032; 1 μM) was added to the medium. For the colony for-
mation assay, cells were fixed with 4% PFA after 7 d in culture and stained
with 0.1% crystal violet. Dried cells were incubated with 10% acetic acid to
solubilize the crystal violet. Absorbance was read at 590 nm. For the cell cy-
totoxicity assay, cells were incubated with CellTox green (catalog no. G8741;
Promega) for 15 min in the dark, after 5 d in culture. The number of dead cells
was measured by using the fluorimeter Synergy HT (BioTek). Immediately after
this first reading, a second reading was taken after incubating the cells for
30 min at 37 °C in Triton X-100 to measure total cell number.
Immunoblot Analysis. Proteins were extracted in radioimmunoprecipitation
assay buffer containing inhibitors of proteases and protein phosphatases.
Extracts (30 μg) were resolved by SDS/PAGE and electrophoretically trans-
ferred to an Immobilon-P membrane (Millipore, Inc.). The membranes were
saturated in 3% nonfat dry milk or 3% BSA (when using phosphospecific
antibodies) and probed overnight at 4 °C with antibodies from Cell Signaling
Technology (1:1,000 dilution, unless indicated otherwise) to pERK1/2 (cata-
log no. 4370), ERK1/2 (catalog no. 4695), ERK5 (catalog no. 3372), STAT3
(catalog no. 12640), pSTAT3-Y705 (1:2,000; catalog no. 9145), pSTAT3-S727
(catalog no. 9134), pJAK2-Y1007/1008 (catalog no. 3771), JAK2 (catalog no.
3230), GFP (catalog no. 2956), SOCS3 (catalog no. 2923), or tubulin (catalog
no. 2125) or with an antibody from Santa Cruz to ERK2 (1:500; catalog no.
C-14). Immunocomplexes were detected by enhanced chemiluminescence
with IgG coupled to horseradish peroxidase as the secondary antibody
(GE Healthcare).
Quantitative Real-Time PCR. Total RNA was isolated from cells by using the
RNeasy kit (Qiagen), and cDNA synthesis was carried out, as described (17).
Quantitative real-time PCRs were performed by using the SYBR Green I Core
Kit (Eurogentec). Sequences of the forward and reverse primers are indicated
in Table S1. PCR products were detected in the ABI-PRISM 7700 sequence
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detection systems (Applied Biosystems). Results were analyzed by using the
2−ΔΔG method. The level of expression of mRNA was normalized to Gapdh
and Pgk1 mRNA.
Immunohistochemical Analysis of Human Tissues. Four-micrometer-thick hu-
man tissue sectionswere immunostainedwith an antibody from Santa Cruz to
ERK5 (1:100 dilution; catalog no. sc-1284-R clone C-20). The reaction was
revealed by using Novolink Polymer (Leica Microsystems) followed by DAB.
Double immunohistochemistry was performed for detection of ERK5
(1:100 dilution; sc-1286) and p-STAT3(Y705) (1:120 dilution; catalog no. 9145
clone D3A7 from Cell Signaling Technology) in human TAMs (1:50 dilution;
CD163 antibody clone 10D6 from Thermo Scientific). Briefly, after completing
the first immune reaction, the second was visualized by using Mach 4 MR-AP
(Biocare Medical), followed by Ferangi Blue (Biocare Medical) as chromogen
and slightly counterstained with hematoxylin.
Immunofluorescence Analysis of Murine Tumor Grafts. Freshly isolated murine
tumor grafts were fixed and stained with a primary antibody to CD34
(RAM34; dilution 1:50; BD Biosciences) and detected by donkey anti-rat–Cy3
(1:10.000 dilution; Jackson Immuno). Double immunofluorescence was per-
formed for detecting pSTAT3(Y705) in TAMs. Briefly, tumor sections were
stained with the pSTAT3(Y705) antibody described above overnight and
detected with a secondary biotinylated anti-rabbit (1:500 dilution; Vector
Laboratories) and Fluorescein Avidin D (1:200 dilution; Vector Laboratories).
To detect macrophages, tumor sections were stained with anti-Iba1
(1:200 dilution; Abcam catalog no. ab5076) for 1 h followed by a second-
ary biotinylated anti-goat (1:500 dilution; Vector Laboratories) and Texas
Red Avidin D (1:200 dilution; Vector Laboratories). Sections were mounted
with ProLong Gold antifade with DAPI (Molecular Probes). Fluorescence
images were captured by using a Leica DM5000 B microscope. Image analysis
was performed by using ImageJ software.
Data Availability. All data supporting the findings of this study are available
within the main text and Supporting Information or from the corresponding
authors on reasonable request.
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